The Competition Commission of Singapore has reportedly not yet approved of the proposed acquisition of diagnostics service provider RadLink-Asia, instead raiding competition concerns over the deal.
Reports say the CCS issued a statement highlighting potential harms to competition in the diagnostics services industry following the deal. RadLink-Asia would be acquired by Parkway Holdings from its current owner, India-based Fortis Healthcare.
The acquisition was agreed upon last September for $108.6 million.
But both Parkway and RadLink operate in the radiopharmaceutical supply industry, as well as other markets, leading the CCS to open a Phase 2 review of the transaction. The CCS has additionally asked the companies for more information on the merger.
Full content: VCCircle
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Senate Democrats Urge DOJ Investigation into Alleged Big Oil Collusion
May 30, 2024 by
CPI
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI